{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:07:31Z","timestamp":1743091651708,"version":"3.40.3"},"publisher-location":"Cham","reference-count":53,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031646355"},{"type":"electronic","value":"9783031646362"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-64636-2_5","type":"book-chapter","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:02:27Z","timestamp":1724738547000},"page":"55-69","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer"],"prefix":"10.1007","author":[{"given":"Haozhe","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"5","key":"5_CR1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang, Y., Chen, M., Nie, H., Yuan, Y.: PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum. Vaccin. Immunother. 15(5), 1111\u20131122 (2019)","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"5_CR2","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D., Li, L.: PD-1\/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res. 10(3), 727\u2013742 (2020)","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"5_CR3","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida, Y., Agata, Y., Shibahara, K., Honjo, T.: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887\u20133895 (1992)","journal-title":"EMBO J."},{"issue":"10","key":"5_CR4","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.str.2016.06.026","volume":"24","author":"R Pascolutti","year":"2016","unstructured":"Pascolutti, R., Sun, X., Kao, J., Maute, R., Ring, A.M., Bowman, G.R., et al.: Structure and dynamics of PD-L1 and an ultra high-affinity PD-1 receptor mutant. Structure 24(10), 1719\u20131728 (2016)","journal-title":"Structure"},{"issue":"5","key":"5_CR5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., et al.: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8(5), 765\u2013772 (1996)","journal-title":"Int. Immunol."},{"issue":"1","key":"5_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-018-0022-9","volume":"3","author":"D Escors","year":"2018","unstructured":"Escors, D., Gato-Ca\u00f1as, M., Zuazo, M., Arasanz, H., Garc\u00eda-Granda, M.J., Vera, R., et al.: The intracellular signalosome of PD-L1 in cancer cells. Sig Transduct Target Ther. 3(1), 1\u20139 (2018)","journal-title":"Sig Transduct Target Ther."},{"issue":"2","key":"5_CR7","first-page":"1379","volume":"15","author":"Q Peng","year":"2018","unstructured":"Peng, Q., Deng, Z., Pan, H., Gu, L., Liu, O., Tang, Z.: Mitogen-activated protein kinase signaling pathway in oral cancer. Oncol. Lett. 15(2), 1379\u20131388 (2018)","journal-title":"Oncol. Lett."},{"issue":"3","key":"5_CR8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3892\/or.2017.5399","volume":"37","author":"T Doi","year":"2017","unstructured":"Doi, T., Ishikawa, T., Okayama, T., Oka, K., Mizushima, K., Yasuda, T., et al.: The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol. Rep. 37(3), 1545\u20131554 (2017)","journal-title":"Oncol. Rep."},{"issue":"1","key":"5_CR9","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon, S., Labarriere, N.: PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 7(1), e1364828 (2017)","journal-title":"Oncoimmunology."},{"key":"5_CR10","doi-asserted-by":"crossref","unstructured":"Berg J vom, Kobold S. The need for speed: how PD1-blockade only works if T cells are properly activated. Transl. Cancer Res. [Internet], 6(Suppl 6) (2017 ). [cited 2023 Oct 4]. https:\/\/tcr.amegroups.org\/article\/view\/15195","DOI":"10.21037\/tcr.2017.06.55"},{"issue":"11","key":"5_CR11","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.4049\/jimmunol.0900080","volume":"182","author":"S Chikuma","year":"2009","unstructured":"Chikuma, S., Terawaki, S., Hayashi, T., Nabeshima, R., Yoshida, T., Shibayama, S., et al.: PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo1. J. Immunol. 182(11), 6682\u20136689 (2009)","journal-title":"J. Immunol."},{"issue":"1","key":"5_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., et al.: Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol. Cancer 18(1), 10 (2019)","journal-title":"Mol. Cancer"},{"issue":"1","key":"5_CR13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-018-9950-6","volume":"36","author":"QF Manson","year":"2019","unstructured":"Manson, Q.F., Schrijver, W.A.M.E., ter Hoeve, N.D., Moelans, C.B., van Diest, P.J.: Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clin. Exp. Metastasis 36(1), 29\u201337 (2019)","journal-title":"Clin. Exp. Metastasis"},{"key":"5_CR14","doi-asserted-by":"crossref","first-page":"102257","DOI":"10.1016\/j.ctrv.2021.102257","volume":"99","author":"C Boman","year":"2021","unstructured":"Boman, C., Zerdes, I., M\u00e5rtensson, K., Bergh, J., Foukakis, T., Valachis, A., et al.: Discordance of PD-L1 status between primary and metastatic breast cancer: a systematic review and meta-analysis. Cancer Treat. Rev. 99, 102257 (2021)","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"5_CR15","first-page":"5023","volume":"12","author":"X Wang","year":"2016","unstructured":"Wang, X., Teng, F., Kong, L., Yu, J.: PD-L1 expression in human cancers and its association with clinical outcomes. Onco. Targets. Ther. 12(9), 5023\u20135039 (2016)","journal-title":"Onco. Targets. Ther."},{"issue":"4","key":"5_CR16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.devcel.2013.04.021","volume":"25","author":"LM Koontz","year":"2013","unstructured":"Koontz, L.M., Liu-Chittenden, Y., Yin, F., Zheng, Y., Yu, J., Huang, B., et al.: The hippo effector yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev. Cell 25(4), 388\u2013401 (2013)","journal-title":"Dev. Cell"},{"issue":"2","key":"5_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","volume":"25","author":"S Jiao","year":"2014","unstructured":"Jiao, S., Wang, H., Shi, Z., Dong, A., Zhang, W., Song, X., et al.: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25(2), 166\u2013180 (2014)","journal-title":"Cancer Cell"},{"issue":"3","key":"5_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/cr.2014.10","volume":"24","author":"W Zhang","year":"2014","unstructured":"Zhang, W., Gao, Y., Li, P., Shi, Z., Guo, T., Li, F., et al.: VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 24(3), 331\u2013343 (2014)","journal-title":"Cell Res."},{"issue":"1","key":"5_CR19","doi-asserted-by":"crossref","first-page":"e99506","DOI":"10.15252\/embj.201899506","volume":"38","author":"A Wu","year":"2019","unstructured":"Wu, A., Wu, Q., Deng, Y., Liu, Y., Lu, J., Liu, L., et al.: Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion. EMBO J. 38(1), e99506 (2019)","journal-title":"EMBO J."},{"key":"5_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-genet-120213-092314","volume":"48","author":"M Gerlinger","year":"2014","unstructured":"Gerlinger, M., McGranahan, N., Dewhurst, S.M., Burrell, R.A., Tomlinson, I., Swanton, C.: Cancer: evolution within a lifetime. Annu. Rev. Genet. 48, 215\u2013236 (2014)","journal-title":"Annu. Rev. Genet."},{"issue":"11","key":"5_CR21","first-page":"283","volume":"23","author":"JK Lee","year":"2016","unstructured":"Lee, J.K., Choi, Y.L., Kwon, M., Park, P.J.: Mechanisms and consequences of cancer genome instability: lessons from genome sequencing studies. Annu. Rev. Pathol. 23(11), 283\u2013312 (2016)","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"5_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-cancerbio-050216-121919","volume":"1","author":"DM Fitzgerald","year":"2017","unstructured":"Fitzgerald, D.M., Hastings, P.J., Rosenberg, S.M.: Stress-induced mutagenesis: implications in cancer and drug resistance. Ann. Rev. Cancer Biol. 1(1), 119\u2013140 (2017)","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"7","key":"5_CR23","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1558-5646.2012.01576.x","volume":"66","author":"Y Ram","year":"2012","unstructured":"Ram, Y., Hadany, L.: The evolution of stress-induced hypermutation in asexual populations. Evolution 66(7), 2315\u20132328 (2012)","journal-title":"Evolution"},{"issue":"1","key":"5_CR24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molcel.2019.05.003","volume":"75","author":"ML Suv\u00e0","year":"2019","unstructured":"Suv\u00e0, M.L., Tirosh, I.: Single-Cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol. Cell 75(1), 7\u201312 (2019)","journal-title":"Mol. Cell"},{"issue":"7965","key":"5_CR25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish, A., Tyler, M., Greenwald, A.C., Hoefflin, R., Simkin, D., Tschernichovsky, R., et al.: Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 618(7965), 598\u2013606 (2023)","journal-title":"Nature"},{"issue":"6","key":"5_CR26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","volume":"48","author":"JD Campbell","year":"2016","unstructured":"Campbell, J.D., Alexandrov, A., Kim, J., Wala, J., Berger, A.H., Pedamallu, C.S., et al.: Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48(6), 607\u2013616 (2016)","journal-title":"Nat. Genet."},{"issue":"9","key":"5_CR27","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3389\/fimmu.2018.01774","volume":"30","author":"H Yao","year":"2018","unstructured":"Yao, H., Wang, H., Li, C., Fang, J.Y., Xu, J.: Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front. Immunol. 30(9), 1774 (2018)","journal-title":"Front. Immunol."},{"issue":"5","key":"5_CR28","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","volume":"23","author":"P Dobosz","year":"2022","unstructured":"Dobosz, P., St\u0119pie\u0144, M., Golke, A., Dzieci\u0105tkowski, T.: Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int. J. Mol. Sci. 23(5), 2847 (2022)","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"5_CR29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder, E.I., Desai, A.: CTLA-4 and PD-1 pathways. Am. J. Clin. Oncol. 39(1), 98\u2013106 (2016)","journal-title":"Am. J. Clin. Oncol."},{"issue":"10","key":"5_CR30","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.7150\/jca.24577","volume":"9","author":"H Zhang","year":"2018","unstructured":"Zhang, H., Chen, J.: Current status and future directions of cancer immunotherapy. J. Cancer 9(10), 1773\u20131781 (2018)","journal-title":"J. Cancer"},{"issue":"7965","key":"5_CR31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41586-023-06110-8","volume":"618","author":"J Zhu","year":"2023","unstructured":"Zhu, J., Naulaerts, S., Boudhan, L., Martin, M., Gatto, L., Van den Eynde, B.J.: Tumour immune rejection triggered by activation of \u03b12-adrenergic receptors. Nature 618(7965), 607\u2013615 (2023)","journal-title":"Nature"},{"issue":"10","key":"5_CR32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nrclinonc.2013.158","volume":"10","author":"EA Kuczynski","year":"2013","unstructured":"Kuczynski, E.A., Sargent, D.J., Grothey, A., Kerbel, R.S.: Drug rechallenge and treatment beyond progression\u2014implications for drug resistance. Nat. Rev. Clin. Oncol. 10(10), 571\u2013587 (2013)","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"140","key":"5_CR33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"1","author":"MG Levra","year":"2020","unstructured":"Levra, M.G., Cott\u00e9, F.E., Corre, R., Calvet, C., Gaudin, A.F., Penrod, J.R., et al.: Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 1(140), 99\u2013106 (2020)","journal-title":"Lung Cancer"},{"issue":"7","key":"5_CR34","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/cancers15072101","volume":"15","author":"DE Kiousi","year":"2023","unstructured":"Kiousi, D.E., Kouroutzidou, A.Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., et al.: The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions. Cancers 15(7), 2101 (2023)","journal-title":"Cancers"},{"issue":"3","key":"5_CR35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0000000000000656","volume":"30","author":"TT Wind","year":"2020","unstructured":"Wind, T.T., Gacesa, R., Vich Vila, A., de Haan, J.J., Jalving, M., Weersma, R.K., et al.: Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Res. 30(3), 235 (2020)","journal-title":"Melanoma Res."},{"issue":"6","key":"5_CR36","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., et al.: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28(6), 1368\u20131379 (2017)","journal-title":"Ann. Oncol."},{"issue":"6371","key":"5_CR37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., et al.: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371), 97\u2013103 (2018)","journal-title":"Science"},{"issue":"1","key":"5_CR38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi, X.W., Wang, H., Zhang, W.W., Wang, J.H., Liu, W.J., Xia, Z.J., et al.: PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J Hematol. Oncol. 9(1), 109 (2016)","journal-title":"J Hematol. Oncol."},{"issue":"8","key":"5_CR39","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","volume":"105","author":"DYW Lin","year":"2008","unstructured":"Lin, D.Y.W., Tanaka, Y., Iwasaki, M., Gittis, A.G., Su, H.P., Mikami, B., et al.: The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Nat. Acad. Sci. 105(8), 3011\u20133016 (2008)","journal-title":"Proc. Nat. Acad. Sci."},{"issue":"12","key":"5_CR40","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak, K.M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., et al.: Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23(12), 2341\u20132348 (2015)","journal-title":"Structure"},{"issue":"11","key":"5_CR41","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2174\/1381612823666161116125218","volume":"23","author":"VR Sharma","year":"2017","unstructured":"Sharma, V.R., Gupta, G.K., Sharma, A.K., Batra, N., Sharma, D.K., Joshi, A., et al.: PI3K\/Akt\/mTOR intracellular pathway and breast cancer: factors, mechanism and regulation. Curr. Pharm. Des. 23(11), 1633\u20131638 (2017)","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"5_CR42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen, J., Jiang, C.C., Jin, L., Zhang, X.D.: Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27(3), 409\u2013416 (2016)","journal-title":"Ann. Oncol."},{"key":"5_CR43","doi-asserted-by":"crossref","unstructured":"Chakrabarti, J., Holokai, L., Syu. L., Steele, N.G., Chang, J., Wang, J., et al.: Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 9(100), 37439\u201337457 (2018)","DOI":"10.18632\/oncotarget.26473"},{"issue":"27","key":"5_CR44","doi-asserted-by":"crossref","first-page":"19177","DOI":"10.18632\/oncotarget.24951","volume":"9","author":"AM Martin","year":"2018","unstructured":"Martin, A.M., Nirschl, C.J., Polanczyk, M.J., Bell, W.R., Nirschl, T.R., Harris-Bookman, S., et al.: PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 9(27), 19177\u201319191 (2018)","journal-title":"Oncotarget"},{"issue":"2","key":"5_CR45","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., Riley, J.L.: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation1. J. Immunol. 173(2), 945\u2013954 (2004)","journal-title":"J. Immunol."},{"issue":"7","key":"5_CR46","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich, K.J., Yoon, H., Ahmed, R., Boss, J.M.: NFATc1 regulates programmed death-1 expression upon T cell activation. J. Immunol. 181(7), 4832\u20134839 (2008)","journal-title":"J. Immunol."},{"issue":"10","key":"5_CR47","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"AL Kinter","year":"2008","unstructured":"Kinter, A.L., Godbout, E.J., McNally, J.P., Sereti, I., Roby, G.A., O\u2019Shea, M.A., et al.: The common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181(10), 6738\u20136746 (2008)","journal-title":"J. Immunol."},{"key":"5_CR48","doi-asserted-by":"crossref","unstructured":"Cho, H.Y., Lee, S.W., Seo, S.K., Choi, I.W., Choi, I., Lee, S.W.: Interferon-sensitive response element (ISRE) is mainly responsible for IFN-\u03b1-induced upregulation of programmed death-1 (PD-1) in macrophages. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1779(12), 811\u2013819 (2008)","DOI":"10.1016\/j.bbagrm.2008.08.003"},{"key":"5_CR49","doi-asserted-by":"crossref","unstructured":"Yee, D., Shah, K.M., Coles, M.C., Sharp, T.V., Lagos. D.: MicroRNA-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J. Biol. Chem. 292(50), 20683\u201320693 (2017)","DOI":"10.1074\/jbc.M117.809053"},{"issue":"3","key":"5_CR50","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.182.3.1325","volume":"182","author":"AY Gong","year":"2009","unstructured":"Gong, A.Y., Zhou, R., Hu, G., Li, X., Splinter, P.L., O\u2019Hara, S.P., et al.: MicroRNA-513 regulates B7\u2013H1 translation and is involved in IFN-\u03b3-induced B7\u2013H1 expression in cholangiocytes. J. Immunol. 182(3), 1325\u20131333 (2009)","journal-title":"J. Immunol."},{"issue":"1","key":"5_CR51","doi-asserted-by":"crossref","first-page":"P53","DOI":"10.1186\/2051-1426-1-S1-P53","volume":"1","author":"J Grosso","year":"2013","unstructured":"Grosso, J., Inzunza, D., Wu, Q., Simon, J., Singh, P., Zhang, X., et al.: Programmed death-ligand 1 (PD-L1) expression in various tumor types. J. ImmunoTher. Cancer. 1(1), P53 (2013)","journal-title":"J. ImmunoTher. Cancer."},{"issue":"5","key":"5_CR52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(20)30207-2","volume":"21","author":"F Barlesi","year":"2020","unstructured":"Barlesi, F., Tomasini, P.: Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors. Lancet Oncol. 21(5), 607\u2013608 (2020)","journal-title":"Lancet Oncol."},{"key":"5_CR53","doi-asserted-by":"crossref","unstructured":"Jalali, S., Price-Troska, T., Bothun, C., Villasboas, J., Kim, H.J., Yang, Z.Z., et al.: Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 9(3), 22 (2019)","DOI":"10.1038\/s41408-019-0185-9"}],"container-title":["Lecture Notes in Computer Science","Bioinformatics and Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-64636-2_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:04:53Z","timestamp":1728986693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-64636-2_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031646355","9783031646362"],"references-count":53,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-64636-2_5","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"type":"print","value":"0302-9743"},{"type":"electronic","value":"1611-3349"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"28 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author declares no conflicts of interest regarding this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Statement"}},{"value":"IWBBIO","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Work-Conference on Bioinformatics and Biomedical Engineering","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Gran Canaria","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Spain","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2024","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"15 July 2024","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"17 July 2024","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"11","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"iwbbio2024","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/iwbbio.ugr.es\/","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}